Skip to main content

Drug Interactions between sodium iodide-i-131 and Urobiotic-250

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sodium iodide I-131 sulfamethizole

Applies to: sodium iodide-i-131 and Urobiotic-250 (oxytetracycline / phenazopyridine / sulfamethizole)

Sulfamethizole may affect the diagnostic results of sodium iodide I-131. Talk to your doctor before you are scheduled for testing to find out if and for how long you should stop using sulfamethizole so that it does not interfere with sodium iodide I-131 test results. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food/lifestyle interactions

Moderate

sodium iodide I-131 food/lifestyle

Applies to: sodium iodide-i-131

Iodine may interfere with the uptake of sodium iodide I-131 by the thyroid . A diet low in iodine and iodinated salt is recommended before starting therapy with sodium iodide I-131.

Moderate

oxytetracycline food/lifestyle

Applies to: Urobiotic-250 (oxytetracycline / phenazopyridine / sulfamethizole)

Do not take iron supplements, multivitamins, calcium supplements, antacids, or laxatives within 2 hours before or after taking oxytetracycline. These products can make oxytetracycline less effective in treating your infection. Do not take oxytetracycline with milk or other dairy products, unless your doctor has told you to. Dairy products can make it harder for your body to absorb the medication.

Moderate

sodium iodide I-131 food/lifestyle

Applies to: sodium iodide-i-131

Multivitamin with minerals may affect the diagnostic results of sodium iodide I-131. Talk to your doctor before you are scheduled for testing to find out if and for how long you should stop using multivitamin with minerals so that it does not interfere with sodium iodide I-131 test results. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

oxytetracycline food/lifestyle

Applies to: Urobiotic-250 (oxytetracycline / phenazopyridine / sulfamethizole)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: The oral bioavailability of quinolone and tetracycline antibiotics may be reduced by concurrent administration of preparations containing polyvalent cations such as aluminum, calcium, iron, magnesium, and zinc. Therapeutic failure may result. The proposed mechanism is chelation of quinolone and tetracycline antibiotics by di- and trivalent cations, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. Reduced gastrointestinal absorption of the cations should also be considered.

MANAGEMENT: Concomitant administration of oral quinolone and tetracycline antibiotics with preparations containing aluminum, calcium, iron, magnesium, and/or zinc salts should generally be avoided. Otherwise, the times of administration should be staggered by as much as possible to minimize the potential for interaction. Quinolones should typically be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation preparations, depending on the quinolone and formulation. Likewise, tetracyclines and polyvalent cation preparations should typically be administered 2 to 4 hours apart. The prescribing information for the antibiotic should be consulted for more specific dosing recommendations.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.